| P50 | author | Didier Hannequin | Q32424966 |
| | Pierre-Marie Preux | Q49996439 |
| | Benoit Marin | Q56862589 |
| | Pierre Clavelou | Q72631651 |
| | Philippe Corcia | Q77535028 |
| P2093 | author name string | Christine Tranchant | |
| | William Camu | |
| | Fausto Viader | |
| | Philippe Couratier | |
| | Jean-Christophe Antoine | |
| | Marie Nicol | |
| | Véronique Danel-Brunaud | |
| | Geraldine Lautrette | |
| | Katell Beauvais | |
| | Bello Hamidou | |
| | Giroud Maurice | |
| | Marie-Christine Arnes-Bes | |
| P2860 | cites work | Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study | Q22306516 |
| | Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) | Q24201081 |
| | Natural history and clinical features of the flail arm and flail leg ALS variants | Q24647753 |
| | Phase II/III randomized trial of TCH346 in patients with ALS | Q28241484 |
| | The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS | Q28296729 |
| | Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research | Q33762409 |
| | Incidence of amyotrophic lateral sclerosis in Europe | Q33774202 |
| | Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial | Q34436090 |
| | Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. | Q34584573 |
| | Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients | Q34699979 |
| | The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset | Q37107393 |
| | Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? | Q38260277 |
| | Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial | Q39344567 |
| | Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis | Q42912800 |
| | Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial | Q43239620 |
| | A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. | Q43991574 |
| | A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 |
| | Motor cortex stimulation for ALS: a double blind placebo-controlled study | Q44804216 |
| | Modeling drop-outs in amyotrophic lateral sclerosis. | Q45906274 |
| | Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis | Q46657553 |
| | Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial | Q46886269 |
| | Pilot trial of clenbuterol in spinal and bulbar muscular atrophy | Q46959815 |
| | The ALSFRSr predicts survival time in an ALS clinic population | Q47867763 |
| | What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis | Q48033371 |
| | A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results | Q49124072 |
| | The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 |
| | Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. | Q55041563 |
| | The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis | Q56773744 |
| | A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis | Q57666978 |
| | Functional scales: Summary | Q58125316 |
| | Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics | Q58125542 |
| P433 | issue | 7-8 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 519-527 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | Q23928840 |
| P1476 | title | Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment | |
| P478 | volume | 18 | |